Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-06 03:26:37 - browse：1459

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： What we’ve learned from the Aduhelm mess

hotspot

WSS

Industry veterans launch new biotech VC with $310M

Medical mystery: When a cough is not just a cough

Black vets could get higher VA benefits if race not used in lung test

Private equity deals in Medicare Advantage declines

BioAge raises $170M for combination therapy with Zepbound

AI for drug discovery: Experts on separating hype from reality

hotspot

Wikipedia

entertainment

At least 13 dead in Texas as scorching temps continue

As billionaires fund anti

Moonlake's readout produced a cash windfall. Risks remain

AltruBio raises $225 million to develop ulcerative colitis drug

Medicare details structure of new drug price negotiation program

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Guidelines to prevent youth baseball injuries need more muscle

Lawmakers grill UnitedHealth CEO on Change cyberattack

Bright Health sells Medicare Advantage business to Molina

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

knowledge

PhRMA lawsuit over Medicare drug price negotiation tossed

Gilead might be held responsible for not developing a drug

Can gargling with Listerine treat gonorrhea of the mouth?

Medicare threatens to cut off funding for HCA's Mission hospital

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Deliver public health messages at the right time

Wikipedia

leisure time

hotspot

entertainment